Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Heart failure in patients treated with bisphosphonates

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Women Living with HIV in high-income settings and Breastfeeding

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Effectiveness of maternal immunization with trivalent inactivated influenza vaccine in pregnant women and their infants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Phenotypic and genotypic differences between Indian and Scandinavian women with gestational diabetes mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates. DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group. The risk of heart failure was estimated by Cox proportional hazard analyses. RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively. The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P 
OriginalsprogEngelsk
TidsskriftJournal of Internal Medicine
Vol/bind274
Udgave nummer4
Sider (fra-til)342-50
Antal sider9
ISSN0954-6820
DOI
StatusUdgivet - okt. 2013

ID: 38706644